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Aims: To test whether a long-acting GLP-1 receptor agonist would improve glucose
control in patients with type 1 diabetes (T1D) and to determine whether the presence
of residual beta cell function would affect the response. In addition, we sought to
determine whether the drug would affect beta cell function.
Methods: We performed a randomized placebo-controlled trial of exenatide
extended release (ER) in participants with T1D with and without detectable levels of
C-peptide. Seventy-nine participants were randomized to exenatide ER 2 mcg
weekly, or placebo, stratified by the presence or absence of detectable C-peptide
levels. The primary outcome was the difference in glycated haemoglobin (HbA1c)
levels at 24 weeks. Participants were followed for another 6 months off study drug.
Results: At week 24, the time of the primary outcome, the least squares (LS) mean
HbA1c level was 7.76% (95% confidence interval [CI] 7.42, 8.10) in the exenatide ER
group versus 8.0% (95% CI 7.64, 8.35) in the placebo group (P = 0.08). At week 12
the LS mean HbA1c levels were 7.71% (95% CI 7.37, 8.05) in the exenatide ER group
versus 8.05% (95% CI 7.7, 8.4) in the placebo group (P = 0.01). The improvement at
week 12 was driven mainly by those with detectable levels of C-peptide. Those
treated with exenatide ER lost weight at 12 and 24 weeks compared to those treated
with placebo (P <0.001 and P = 0.007). The total insulin dose was lower, but not
when corrected for body weight, and was not affected by residual insulin production.
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Adverse events were more frequent with exenatide ER, but hypoglycaemia was not
increased.
Conclusion: Treatment with exenatide ER may have short-term benefits in some indi-
viduals with T1D who are overweight or who have detectable levels of C-peptide,
but short-term improvements were not sustained.
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1 | INTRODUCTION
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have become
widely used for the treatment of type 2 diabetes.1–4 Their metabolic
actions involve augmenting glucose-stimulated insulin release, inhibi-
tion of glucagon secretion, and slowed gastric emptying. The drug
class has been found to have additional therapeutic benefits such as
weight loss and reduced major cardiovascular disease events in sev-
eral large randomized controlled trials.5
The metabolic properties of these agents might also be of value
for patients with type 1 diabetes (T1D), particularly those with resid-
ual insulin production. Many patients, even those with long-standing
T1D, may have detectable levels of C-peptide well beyond the new-
onset period.6,7 Tropic effects of exendin-4 on β cells were shown in
rodents after partial pancreatectomy, and synergy with immune ther-
apy at the time of diabetes onset enhanced the insulin content of β
cells.8,9 Data from human studies have identified impaired function of
residual β cells in patients with T1D, thus further supporting a poten-
tial use of GLP-1RAs in these patients.10
The results from previous clinical trials of GLP-1RAs in patients
with T1D, however, were inconclusive. Sarkar et al11 reported that
exenatide treatment given four times daily for 6 months in adults with
T1D improved insulin sensitivity, assessed by hyperinsulinaemic-
euglycaemic clamp, and reduced postprandial glucose levels, although
fasting glucose levels were increased. In the ADJUNCT ONE study,
liraglutide, administered once daily at three dosing levels, added to
insulin therapy in patients with T1D, reduced glycated haemoglobin
(HbA1c) levels, total daily insulin dose and body weight but increased
the rates of hypoglycaemia and hyperglycaemia with ketosis.12 Similar
data were reported in the ADJUNCT TWO study, evaluating 1.2 or
1.8 mg/d of liraglutide added to capped insulin therapy.13 Recently,
short-acting exenatide did not improve HbA1c levels when given for
26 weeks as add-on therapy to insulin-treated patients with T1D.14
A possible reason for these inconclusive data is that the metabolic
effects of GLP-1RAs, particularly the augmentation of insulin produc-
tion, might only be of value to patients with residual insulin produc-
tion. In the ADJUNCT ONE trial, those with detectable C-peptide at
baseline had improved responses to liraglutide compared to those
without.12 In an earlier study, we analysed the acute metabolic effects
of exenatide in patients with T1D during mixed-meal tolerance tests
and observed a marked improvement in glucose excursion in response
to oral but not to intravenous glucose.15 In those with residual insulin
production, there was a relative increase in insulin secreted in
response to glucose, most likely related to the reduced glucose excur-
sion because the total amount of insulin secreted did not change with
exenatide. To date, the metabolic effects of GLP-1RAs specifically
comparing patients with T1D with and without residual insulin pro-
duction, have not been directly studied. In addition, newer agents
with weekly dosing may have a greater impact on fasting blood sugars
and decreased burden of use.
We therefore conducted a randomized placebo-controlled trial to
determine whether the long-acting GLP-1RA, exenatide extended
release (ER), affected metabolic control in patients with stable man-
agement of T1D and whether there were differences in the responses
in patients with and without detectable levels of endogenous insulin
production, that is, with detectable C-peptide levels.
2 | RESEARCH DESIGN AND METHODS
2.1 | Trial design
A randomized double-blind phase 2b study of 2 mg exenatide ER sub-
cutaneously weekly or matched placebo for 24 weeks in patients with
T1D was conducted at seven academic sites in the United States
between September 2013 and November 2017. The clinical trial was
approved by the institutional review boards at each of the clinical
sites and the participants signed written consent. The trial was regis-
tered at ClinicalTrials.gov: NCT01928329.
Eligible patients were 18 years and older with “stable” T1D of at
least 2 years' duration (defined as insulin requirement <0.9 U/kg/d, an
HbA1c of <9.0% and absence of diabetic ketoacidosis in the past
6 months; Table S1). Exclusion criteria included pregnancy, a personal
or family history of multiple endocrine neoplasia type 2, history of
pancreatitis, gastroparesis or other gastrointestinal disturbances,
abnormal liver function tests, renal impairment, active infection, use
of other antidiabetic medications other than insulin, or a history of
severe hypoglycaemia.
A total of 79 patients were enrolled. They were screened for
detectable levels of C-peptide in response to a mixed-meal tolerance
test (MMTT), performed with a liquid meal (Boost) using described
methods16: 33 patients had a level during the test of ≥0.017 nmol/L
and 46 had levels <0.017 nmol/L (0.05 ng/mL), the lower limit of
detection in the C-peptide assay (Figure 1, Table S1). The patients
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were randomized 1:1 to treatment arms within the two strata. The
two treatment arms were subcutaneous exenatide ER 2 mcg/wk or
matched subcutaneous placebo. The patients were asked to reduce
insulin by half after initiating study drug and then to change the dos-
ing in discussion with their physician. At week 24, the patients discon-
tinued the study drug and were followed for another 24 weeks.
Compliance was assessed through query by the study staff at
each visit. Diabetes management was left to the patients' care pro-
viders; all received “intensive” management of their diabetes in line
with the current American Diabetes Association (ADA) standards.17
Drug discontinuation was specified in the study protocol for the
following reasons: nausea or vomiting that precluded adherence to
diet; three severe hypoglycaemic reactions on separate days (requiring
assistance from another individual); weight loss of ≥5 kg from base-
line; or any grade 3 or higher adverse event that prevented comple-
tion of the treatments.
2.2 | Assessments
After the screening visit, the patients were seen at weeks 2, 4, 12, 24,
38 and 52. C-peptide and glucose levels were measured during the
120-minute MMTT at weeks 12, 24 and 52. The average insulin use
per day was determined from patient diaries that recorded insulin use
for 3 days prior to a study visit. Insulin use was expressed as the total
units or units/kg/d. Hypoglycaemia was graded according to the
Common Terminology Criteria for Adverse Events (version 4).
Hypoglycaemia was captured from patient diaries, with glucose mea-
surements up to six times daily for 3 days prior to study visits or with
symptoms. Severe hypoglycaemia was designated if assistance from
others was required for recovery, or if it resulted in hospitalization or
seizure.
Two-hour MMTTs were performed at each study visit. HbA1c
and C-peptide (Tosoh assay) levels were measured at the Northwest
Lipid Research Laboratory. In a subgroup of patients, glucagon levels
were measured with the Millipore assay (n = 29) and glucagon-like
peptide (GLP) and gastric inhibitory peptide (GIP) by ELISA (n = 35) in
the Yale Diabetes Center Core Laboratory.
2.3 | Outcome measures and statistical analysis
The primary outcome was a comparison of the HbA1c levels,
corrected for the baseline, between the two treatment arms at
24 weeks. Prespecified secondary outcomes at 24 weeks included:
change in weight; change in total daily insulin dose; C-peptide and
glucose responses during the MMTTs; frequency of hypoglycaemia;
and other adverse events, with a comparison within and between
patients with and without detectable C-peptide at entry.
The original target sample size calculation was based on repeated
measures of HbA1c in patients with T1D in our clinic in which the
standard deviation (SD) of the HbA1c level was 1.25% and the
Assessed for eligibility (n=90), 
screened for detectable C-
peptide 
Not enrolled because of exclusion 
criteria (n=11)
Analysed  (n=40)
Discontinued intervention (adverse event, n=5, 
weight loss, n=4, withdrew consent, n=1, non-
compliance, n=1) 
Allocated to Exenatide ER (n=40) 
Received allocated intervention (n=39)♦
♦ Did not receive allocated intervention 
(withdrew consent) (n=1) 
23 C-pep–, 15 C-pep+ 
Discontinued intervention (adverse event, n=3, 
weight loss, n=1, withdrew consent, n=5, other 
illness, n=1) 
Allocated to placebo (n=39) 
Received allocated intervention (n=35)
Did not receive allocated intervention 
(withdrew consent, n=3, removed by 
investigator, n=1) 









F IGURE 1 CONSORT diagram
showing flow through the clinical
study. C-pep–, without detectable
C-peptide; C-pep+, with detectable
C-peptide
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correlation between measurements of HbA1c, performed 24 weeks
apart, was 0.88. A sample size of 54 patients per group would have
provided 90% power to detect a difference of HbA1c of 0.4%
between the study arms. Because of rates of enrolment, the original
planned 120 participants was reduced to 79 participants. This gave us
79% power to detect a difference of 0.40% in HbA1c.
The final analysis involved all enrolled patients. A likelihood-based
ignorable analysis using a linear mixed model was used to compare
HbA1c between groups.18,19 The analysis assumed that missing data
occurred at random. Fixed effects for treatment arm, time (12, 24 and
52 weeks), and the interaction of treatment with time were tested
with additional fixed effects for baseline covariates (baseline HbA1c,
detectable/non-detectable baseline C-peptide, site, gender, race, body
mass index). A linear model compared the least squares (LS) means of
exenatide ER to placebo at 24 weeks between groups at the two-
sided 0.05 significance level. In subgroup analysis to determine
whether the presence of residual insulin production affected treat-
ment response, two- and threeway interactions of that stratification
factor with treatment and time were evaluated using a multiple
degree of freedom likelihood ratio test at the 0.10 significance level.
Linear mixed effect models similar to those described above were
used to evaluate continuous secondary outcomes. For hypoglycaemic
events, the number of months that an individual was on and off study
drug was used to calculate an event rate (rate = total events/total
months). To compare these rates between treatment arms, the
Mann–Whitney test was used. The number of patients that experi-
enced severe adverse events on and off study drug were compared
using Fisher's exact test. Adjustments were not made for multiple
comparisons for secondary outcomes.
2.3.1 | Role of the funding source
The funders were not involved in the design or execution of the study,
collection of the data, writing of the manuscript, participation in the
Data Safety Monitoring Board, or the decision to submit the manu-
script for publication.
3 | RESULTS
3.1 | Study participants
The baseline characteristics and flow of patients in the trial are shown
in Figure 1 and Table S1. Of the 79 enrolled patients, five were
randomized but never received study drug. (Four withdrew consent
and one was withdrawn by the study team.) Twenty-one patients
(28%) discontinued the study drug during the first 6 months. The
reasons cited for discontinuation were: adverse events (n=8), with-
drawn consent or ineligibility (n=6), weight loss >5 kg (n=5), unrelated
illness (n=1) and non-compliance with insulin regimen (n=1).
The study participants' age at T1D diagnosis ranged from 2 to
50 years. Their mean (SD) baseline body weight was 83.7 (21.7) kg in
the exenatide ER group and 84.13 (22.6) in the placebo group. There
were no significant differences in baseline characteristics between
those randomized to exenatide ER versus those randomized to pla-
cebo treatment. The mean (SD) baseline HbA1c (7.60 [±0.82]%), and
daily insulin use (0.59 [0.18] U/kg/d) were consistent with features of
individuals with long-standing T1D. Insulin delivery methods were
similar in the two treatment arms: 20 patients (25.3%) were using mul-
tiple daily injections and 58 (73.4%) were using pumps.
Overall, 42% (33 patients) had detectable C-peptide levels at
screening (Table S1B). These patients had shorter duration of T1D
(mean [SD] 14.9 [10.9] years) compared to those without detectable
C-peptide levels (mean [SD] 22.8 [10.3] years; P = 0.002). Among
those with detectable C-peptide, those randomized to exenatide ER
treatment had a significantly lower HbA1c at baseline (P = 0.03), but
otherwise there were no significant differences between the
subgroups.
3.2 | Primary outcome
At the primary endpoint, week 24, the effects of exenatide ER were
not statistically different compared to placebo (group differences
−0.237 [95% CI 0.50, 0.03], LS mean 7.76% [95% CI 7.42, 8.10] in the
exenatide ER group vs. 8.0% [95% CI 7.64, 8.35] in the placebo group;
P = 0.08 [Figure 2A]). Exenatide ER treatment did have a rapid initial
effect on the HbA1c. There was a significant decline in the active drug
arm from baseline to 12 weeks (an LS mean difference −0.179% [95%
CI −0.352, −0.004]), and a difference in the HbA1c levels of 7.71%
(95% CI 7.37, 8.05) versus 8.05% (95% CI 7.7, 8.4) between exenatide
ER and placebo, respectively (P = 0.01). In the observational follow-up
at week 52, 24 weeks after study drug discontinuation, the HbA1c
level increased in the exenatide ER group to the pretreatment levels.
The decline in HbA1c at 12 weeks was largely driven by those
with detectable C-peptide (mean −0.51% [95% CI −0.827, −0.184];
P = 0.0025 vs. baseline) versus those without detectable C-peptide
(mean −0.143% [95% CI −0.447, 0.162]), but the differences between
those with and without detectable C-peptide were not statistically
significant at that time (mean 0.363 [95% CI −0.08, 0.806]; P = 0.107)
or at 24 weeks (mean −0.101% [95% CI −0.68, 0.479]; P = 0.73 [Fig-
ure 2B]). At 52 weeks, the declines in HbA1c from the baseline were
<0.1% in both subgroups.
3.3 | Secondary outcomes
Daily insulin dose declined significantly at 12 weeks in the
exenatide ER group compared to baseline (P = 0.04; Figure 3A). At
the same time, the total daily insulin dose increased in the placebo
group, leading to a significant difference at week 24 when the two
treatment arms were compared (P = 0.025). The difference
between the treatment arms continued even at 52 weeks due to an
increase in insulin use among those originally assigned to placebo
treatment (P <0.001).















































F IGURE 2 Effects of exenatide extended release (ER) treatment on glycated haemoglobin (HbA1c) levels. A, HbA1c levels in the two
treatment arms at each study visit. There was a significant reduction in the HbA1c level in the exenatide ER group at 12 weeks (P = 0.045) and
the levels were significantly different from the placebo group (P = 0.01). However, at 24 weeks, the differences between the groups were not
statistically significant (P = 0.08). B, In those with a detectable level of C-peptide (C-pep+) at baseline (C-peptide ≥0.017 nmol/L), there was a
significant reduction, compared to baseline, in the HbA1c level at 12 weeks (P = 0.0025) but not in those with undetectable C-peptide levels
(C-pep–; C-peptide < 0.017 nmol/L). The treatment changes in each subgroup taken from the linear mixed model are shown. All data shown are
from the linear mixed model (mean ± 95% confidence interval)
F IGURE 3 Effects of exenatide extended release (ER) treatment on insulin use and weight. A, The total daily insulin use (U/d) in the two
treatment arms is shown. There was a reduction in the use of insulin in the exenatide ER group at 12 weeks compared to baseline (P = 0.038). At
24 weeks insulin use in the exenatide group was significantly less than in the placebo group (P = 0.025). At 52 weeks insulin use in the placebo
group was increased compared to baseline (P = 0.008) and was significantly greater than in the patients that were treated with exenatide ER
during the first 6 months (P = 0.0009). B, There was significant loss in weight in the exenatide ER- versus the placebo-treated patients at
12 weeks (P = 0.003) and 24 weeks (P = 0.017). C, Insulin use corrected for body weight (U/kg/d). D, A comparison of the treatment difference
(vs. placebo) in the use of insulin in those with (C-pep+) and without detectable C-peptide (C-pep–) at baseline. All data shown are from the linear
mixed models (mean [95% CI])
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At both weeks 12 and 24, those treated with exenatide ER lost
more weight from baseline than those treated with placebo (group dif-
ferences mean −2.93 kg [95% CI −4.33, −1.5]; P <0.0001 and −2.38
kg [95% CI −4.11, −0.644]; P = 0.0078, respectively [Figure 3B]). At
52 weeks, the median weight loss in both treatment arms was <1 kg
compared to baseline weight (exenatide ER −0.176 kg [95% CI
−2,1.65] and placebo 0.52 kg [95% CI −1.45, 2.49]).
When the insulin dose was corrected for body weight, there was
no significant difference with exenatide ER treatment compared to
placebo (Figure 3C). The presence or absence of detectable C-peptide
did not have a significant effect on the change in insulin dose, either
total U/d or U/kg/d, with treatment at 12, 24 or 52 weeks (Figure 3D).
In contrast to that reported for patients with T2D,3 we did not find a
significant relationship between the change in weight and the change
in HbA1c (Figure 1A,B).
The glucose response during the MMTT improved significantly
from baseline at 24 weeks in the exenatide ER-treated patients
(P = 0.04, Figure 4A). However, there was no significant difference
from the glucose areas under the curve (AUCs) in the exenatide ER-
versus the placebo-treated patients at any of the time points.
Among those without detectable C-peptide, the glucose AUC had
declined from baseline at 24 weeks (P = 0.04) and was significantly
lower than among those with detectable C-peptide at 52 weeks
(P = 0.04; Figure 4B). To determine whether the exenatide ER treat-
ment improved insulin secretory responses, we analysed the effects
of exenatide ER on C-peptide responses during the MMTT in those
with detectable levels at baseline. The differences between the
two treatment arms were not significantly different at baseline or
three time points, but there was a trend for improvement in the C-
peptide at 12 weeks between the treatment groups (group differ-
ence = 0.000374 [−0.00004, 0.000791]; P = 0.08). This was attrib-
utable primarily to a decline in the placebo group from baseline
(−0.0003 [−0.00061, 0.000012]; P = 0.06) and there was a signifi-
cant decline at week 52 (P = 0.04) in the placebo group (Figure 4C).
Our previous studies had suggested an improvement in the
C-peptide:glucose ratio with short-acting exenatide, but we did not
F IGURE 4 Effects of exenatide extended release (ER) treatment on glucose and C-peptide responses. A, There was a significant reduction in
the glucose area under the curve (AUC) at week 24 in the exenatide ER group compared to baseline (P = 0.04), but not compared to placebo
(P = 0.1). B, There was a significant improvement, compared to baseline vs. placebo, in the group without detectable C-peptide at week 24
(P = 0.04). At 52 weeks there was a greater effect on the glucose AUC in the patients that did not have detectable C-peptide (C-pep–) compared
to the patients that did (C-pep+; P = 0.04). C, C-peptide AUC (in pmol/mL/min) was compared between the exenatide ER- and placebo-treated
patients by linear mixed model at each of the study time points in those with detectable C-peptide levels at baseline. Data are shown as ln(AUC/
120 min + 1). There was a significant decline at 52 weeks, compared to the baseline, in patients treated with placebo for the first 24 weeks
(P = 0.04). D, C-peptide:glucose ratio was compared in the two treatment arms for those with detectable C-peptide levels at baseline. There was
a modest effect of exenatide ER on the C-peptide/glucose ratio at 12 weeks in comparison with placebo (P = 0.06). Units of nmol/L and mg/dl
were used for calculation of the C-peptide/glucose ratio
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find a significant change or difference between treatment arms
with exenatide ER treatment (Figure 4D).
Plasma glucagon levels were measured before and after therapy
with exenatide ER in nine patients. The glucagon levels did not show
a clear pattern of response, either in the AUC during the MMTT or in
the peak value. In these same patients we did not detect a change in
plasma GIP or GLP levels (Figure S2).
The frequencies of hypoglycaemic events are summarized in
Table 1. Hypoglycaemia was classified using ADA criteria.17 To stan-
dardize these measures, the number of months that an individual was
on and off study drug was used to calculate an event rate (rate = total
events/total months). While on drug, the placebo treatment arm had
higher mean and median rates of minor, major and total hyp-
oglycaemic events compared to the intervention arm, but the fre-
quency of these events was not significantly different. While off
study drug (months 6–12), the placebo treatment arm continued to
have higher mean and median rates of minor, major and total hyp-
oglycaemic events, but were again not significantly different. The fre-
quency and severity of hypoglycaemic events were not evenly
distributed among the patients. One individual, treated with exenatide
ER, had 115 events. Another exenatide ER-treated patient had a grade
3 major event with loss of consciousness.
3.4 | Adverse events
While on study drug, 38 out of 39 patients in the active drug
(exenatide ER) group (97.4%) experienced at least one adverse event,
while in the placebo group, a total of 28 out of 35 patients (80.0%)
experienced at least one adverse event (Table S2; P = 0.02). There
was a significant difference between the drug group (n = 22, 56.4%)
and the placebo group (n = 8, 22.9%) with respect to gastrointestinal
disorders. Skin manifestations were more frequent in the exenatide
ER group. However overall, there were no significant differences
between the treatment groups in the other organ class adverse event
categories nor with respect to grade 3 and grade 4 events.
While off study drug, 29 out of 37 original exenatide ER-treated
patients (78.4%) experienced at least one adverse event, while in
those originally treated with placebo, 25 out of 26 patients (96.2%)
experienced at least one adverse event (P = 0.069). A greater propor-
tion of those in the placebo group (n = 22, 84.6%) compared to the
active treatment group (n = 23, 62.2%) experienced adverse events
related to metabolism and nutrition disorders. There were no signifi-
cant differences between the treatment groups on other organ class-
specific adverse events, nor on grade 3 or grade 4 adverse events dur-
ing the off study drug phase.
There were a total of eight serious adverse events, six in the
exenatide ER arm while taking study drug and two in the placebo
group. One of the events in the exenatide ER arm involved
ketoacidosis. The most frequent serious event was hypoglycaemia.
These events are shown in Table S3. Of the serious adverse events, all
except for the hypoglycaemia were considered unrelated to
study drug.
4 | DISCUSSION
We tested whether treatment with exenatide ER for 24 weeks would
improve glycaemic control in patients with T1D on stable insulin regi-
mens, and examined the role of residual C-peptide in determining the
responses. Because GLP-1RAs improve endogenous glucose-stimu-
lated insulin secretion, we postulated that the effects of the drug
would be greater in those with residual insulin production compared
to those in whom C-peptide was undetectable. We found that the pri-
mary endpoint of the trial, change in HbA1c levels at 24 weeks, was
not significantly different when exenatide ER-treated patients with
TABLE 1 Hypoglycaemic eventsa
Timeframe Arm Variable N Mean SE Median Minimumb Maximumb
On drug Exenatide ER Level 1 hypoglycaemia event rate 39 2.07 0.44 1.00 0 11.33
Level 2 hypoglycaemia event rate 39 1.82 0.50 0.67 0 13.00
Total event rate 39 3.89 0.88 1.33 0 21.67
Placebo Level 1 hypoglycaemia event rate 35 2.60 0.54 1.60 0 13.00
Level 2 hypoglycaemia event rate 35 2.00 0.43 0.80 0 10.50
Total event rate 35 4.59 0.94 2.33 0 23.50
Off drug Exenatide ER Level 1 hypoglycaemia event rate 37 1.09 0.29 0.17 0 8.33
Level 2 hypoglycaemia event rate 37 0.74 0.19 0.33 0 5.00
Total event rate 37 1.83 0.45 0.50 0 11.17
Placebo Level 1 hypoglycaemia event rate 26 1.81 0.53 0.50 0 12.50
Level 2 hypoglycaemia event rate 26 1.62 0.55 0.50 0 13.17
Total event rate 26 3.43 1.05 1.00 0 25.67
aHypoglycaemia was defined using American Diabetes Association criteria (level 1 between 55 mg/dL (3.05 mmol/L) and 70 mg/dL (3.89 mmol/L), level 2
hypoglycaemia ≤55mg/dL (3.05 mmol/L).17
bEvents/study month/person.
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T1D were compared to placebo treatment, but we did find improve-
ment between the treatment arms in the HbA1c levels at 12 weeks
after starting drug therapy. There was no lasting effect on HbA1c, as
levels 6 months after the study drug was discontinued were similar in
the two study arms, suggesting that the continued presence of drug
was needed for metabolic effects. The drug treatment caused weight
loss which resolved when the treatment was discontinued. Total insu-
lin use declined but, when corrected for weight, there was no signifi-
cant difference either between the groups or compared to baseline,
suggesting that the exenatide ER treatment did not improve insulin
sensitivity. Hypoglycaemia was common in all study participants and
there were more severe hypoglycaemic events in the exenatide ER-
treated patients, although the rate was low overall. The frequency of
skin manifestations with exenatide ER injections was higher than with
placebo. There was one episode of diabetic ketoacidosis and three
episodes of hypoglycaemia that were classified as serious adverse
events in the exenatide ER arm. Other adverse events were similar in
the two treatment arms.
The improvement in HbA1c level at 12 weeks was observed in
those with and without residual insulin production at study entry, but
the effect was greater in those with detectable C-peptide. Other mea-
sures, such as insulin use or glucose AUC during the MMTTs, were
not different in those with and without residual insulin production.
Because GLP-1RAs are known to augment insulin production we
predicted a greater treatment effect in those with residual insulin
secretion but, similar to our acute studies, the metabolic effects of the
drug were not limited to those with residual insulin secretion.2,15 Our
findings were similar even when we separately analysed those with
the highest levels of C-peptide at baseline (not shown). Interestingly,
we found a trend in improved C-peptide responses in the exenatide
ER-treated versus the placebo-treated patients in terms of stimulated
responses in the treatment group but also compared to the decline in
the placebo group. This is most likely explained by the relatively short
duration of diabetes in those with detectable C-peptide and the ongo-
ing decline over 1 year, reflective of the natural history of the disease.
Therefore, together with the HbA1c data, these findings suggest but
do not conclusively indicate, that the drug may have additional benefit
in those with residual β-cell function.
The adverse events were consistent with the experience of GLP-
1RAs in T2D, but the rates of hypoglycaemia overall were higher.3,4,20
We observed other differences compared to the described effects in
patients with T2D. First, exenatide ER had been shown to reduce glu-
cagon levels in patients with T2D, but we did not observe this during
the provocative studies.3 This may reflect a relative insensitivity or
dysregulation of α cells in patients with T1D to the effects of the ago-
nist, which had been observed in acute studies.15 In addition, we did
not find a relationship between weight loss and the improvement in
HbA1c or insulin use. There may be additional effects of the drug on
insulin sensitivity in patients with both forms of diabetes, as
suggested by Rother et al.21
Our findings differ from other studies of GLP-1RAs in patients
with T1D. In the ADJUNCT ONE trial, addition of liraglutide to insu-
lin therapy reduced HbA1c levels, total insulin dose and body
weight, but also increased the rates of symptomatic hypoglycaemia
and hyperglycaemia with ketosis.12 In the ADJUNCT TWO trial,
liraglutide, added to capped insulin, reduced HbA1c levels, body
weight and insulin requirements, but with higher rates of
hypoglycaemia and ketosis.13 The differences between the adverse
events in the present study and the ADJUNCT trials may reflect our
reduction in exogenous insulin treatment when the study drug was
initiated, or possibly the differing pharmacokinetics of the GLP-1RAs
given once weekly versus daily. Indeed, with acute administration of
exenatide we found a flattening of the glucose response during an
MMTT, which was not seen in the present study.15 Our findings sug-
gest a more robust response of HbA1c than was seen in the recently
reported trial of exenatide, given three times daily to patients with
T1D.14
The observed rates of hypoglycaemia were high but not higher in
the exenatide ER versus the placebo arm, but there were six severe
hypoglycaemic events in three exenatide ER-treated patients. The
rates were higher in the exenatide ER-treated group on versus off
study drug. This suggests that the reduced need for exogenous insulin
may not affect the rates of hypoglycaemia overall, but there may be
particular individuals at high risk for hypoglycaemia when exenatide
ER is given in addition to insulin.
In the absence of clear enhancement of insulin secretion, reduced
glucagon release, and change in insulin sensitivity with exenatide ER,
the basis for the improvement in HbA1c after 12 weeks remains
unexplained. It is possible that the metabolic effects that we had seen
with the acute administration of exenatide also occurred with the
long-acting formulation of the drug, but were more modest, and that
our assays to detect these effects were limited by the sample size or
that there was tachyphylaxis to the long-term GLP-1RA exposure. It is
also possible that other mechanisms are involved, such as slowing gas-
tric emptying or changes in dietary patterns in response to the gastro-
intestinal adverse events that resulted in improved glycaemic control,
in the short term. Finally, GLP-1RAs have been found to have anti-
inflammatory effects which could account for improved metabolic
control.22 However, we did not find changes in immune cells (CD4,
CD8) or markers of cell activation (RAGE expression) with exenatide
ER treatment (not shown).23
The present study has a number of limitations. The total sample
size was insufficient to detect the difference in the HbA1c level that
we had originally planned. In addition, not all of the patients com-
pleted the 6-month follow-up visit to determine whether any effects
of the drug treatment may have persisted. Furthermore, our study
design did not entail a treat-to-target regimen or capped insulin dose
that had been used in the ADJUNCT trials and, therefore, the man-
agement of the patients may have varied based on the care provider.
Finally, the patients were heterogeneous, as reflected by the shorter
duration of disease in those with residual insulin production, which
may have affected the management patterns or the responses to the
drug. Nonetheless, the patients are representative of those seen in
practice, with clinical features such as increased body mass index and
residual insulin production that might suggest the appropriateness of
a GLP-1RA for treatment.
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In conclusion, in this clinical trial of exenatide ER in patients with
T1D, we did not find a significant improvement in HbA1c after
6 months of treatment, but HbA1c levels were significantly reduced
after 12 weeks. The effects of the drug treatment in the short term
were more pronounced in those with residual insulin production but
not significantly different from those without detectable C-peptide.
Weight loss was common, but the rates of hypoglycaemia were similar
in the two treatment arms. We conclude that adjunctive treatment
with exenatide ER may have value in some individuals with T1D,
mainly those with obesity and in whom there is residual insulin pro-
duction, but the short-term improvements were not sustained. The
reduced dependence on exogenous insulin without increased rates of
hypoglycaemia may make this adjunctive therapy attractive, but cau-
tion should be exercised in view of the higher rates of hypoglycaemia
in some patients. In addition, the emerging beneficial effects of
GLP-1RAs on cardiovascular and renal disease suggest there may be
additional benefits of these agents, but further studies will be needed
to determine whether these other beneficial effects are common to
T1D.24-29
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